Access cutting-edge end stage kidney disease treatment through this clinical trial at a research site in Glendale. Study-provided care at no cost to qualified participants.
Access end stage kidney disease specialists in Glendale at no cost
This study follows strict safety protocols and ethical guidelines
All study-related end stage kidney disease treatment provided free
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Sponsor: CSL Behring
Check if you qualify for this end stage kidney disease clinical trial in Glendale, AZ
If you're searching for end stage kidney disease treatment options in Glendale, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Glendale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced end stage kidney disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.